Profound Medical (NASDAQ: PROF) — Perfil da empresa, notícias e dados financeiros
Profound Medical develops innovative technologies for treating prostate diseases through minimally invasive medical procedures.

Profound Medical
Profound Medical (TSX:PRN), (NASDAQ:PROF) focuses on developing and commercializing medical technologies primarily for the treatment of diseases through minimally invasive procedures. The company's operations span across the design, research, and the deployment of devices aimed at the therapeutic treatment of serious medical conditions, enhancing patient outcomes with a focus on prostate diseases. The company's projects aim at pushing the frontier of medical treatments, ensuring safer, more effective procedures are available. Profound Medical's objectives center around improving patient care, expanding its technological footprint, and ensuring its innovations are accessible and adopted in healthcare systems worldwide, driving a profound impact on medical practices and patient lives.
Resumo
Operações
Produtos e/ou serviços de Profound Medical
- TULSA-PRO, a minimally invasive procedure for prostate tissue ablation combining real-time MRI, robotically-driven ultrasound, and closed-loop thermal feedback control.
- SONALLEVE, an innovative therapeutic platform using MR-guided focused ultrasound (MRgFUS) for the treatment of uterine fibroids and palliation of pain associated with bone metastases.
- A real-time MRI guidance and ultrasound ablation technology designed for precise, controlled treatments of conditions requiring tissue ablation.
- Development and commercialization of customizable MR-guided therapeutic ultrasound applications for a wide range of diseases beyond prostate and uterine conditions.
- Partnerships for advancing its MR-guided therapeutic ultrasound technology in clinical studies for new applications.
- Continuous innovation in medical software for planning, guiding, and monitoring therapeutic interventions to enhance efficacy and safety of treatments.
equipe executiva do Profound Medical
- Arun Swarup MenawatChairman of the Board & CEO
- Mathieu BurtnykChief Technology Officer
- Thomas TamberrinoChief Commercial Officer
- Richard R. FabianPresident
- Matthew SobczykInterim Chief Financial Officer
- Stephen KilmerInvestor Relations
- Levant TinazSoftware Developer
Principais indicadores financeiros
Resultados divulgados pela Profound Medical , em USD.
- Cap. de mercado
- 211,2 mi
- Receita (TTM)
- 19,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.0
- Dividend yield
- —
- Margem de lucro
- -171.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 16,4 mi | -42 mi | -43,3 mi | |
| 10,2 mi | -31,5 mi | -26,5 mi | |
| 7,2 mi | -28,6 mi | -28,6 mi | |
| 6,7 mi | -32,1 mi | -28,7 mi |